Zdrowie i gospodarka · 17/02/2023

FDA Clears Dihydroergotamine Mesylate 45 Injection for Continued Sale

The US Food and Drug Administration (FDA) has ruled that D.H.E. 45 injection, a medication used to treat migraines, will not be removed from the market due to safety or effectiveness concerns, allowing it to remain available for future abbreviated new drug applications (ANDAs).